Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Alimera Sciences (ALIM)

Add ALIM Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 12/14/2017 1:23:44 PM - Followers: 38 - Board type: Free - Posts Today: 0

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to
treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark,
Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom.
In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and
did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.


Fox Business News interview with the CEO accounted for the news. 

FDA approves new diabetes implant 
Apr. 21, 2016 - 3:25 - Alimera Sciences CEO Dan Myers on a new diabetes implant that treats macular degeneration.

Retinal Vein Occlusion (RVO)

ILUVIEN® Patent Notices

Please see the following table for U.S. Patents covering ILUVIEN®. The absence of a U.S. Patent number as associated with ILUVIEN does not constitute a waiver of our patent, trademark, or other intellectual property rights concerning that product.



ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg

U.S. 6,217,895

U.S. 6,375,972

U.S. 6,548,078

U.S. 8,252,307

U.S. 8,574,659

U.S. 8,871,241

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient's eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops ILUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences Inc. is based out of Alpharetta, GA and has some 132 employees.

Officers and directors

Richard S. Eiswirth Jr.   President, Chief Financial Officer
C. Daniel Myers   Chief Executive Officer, Director
Kenneth E Green Ph.D.   Senior Vice President, Chief Scientific Officer
David R Holland   Senior Vice President - Sales and Marketing
Philip Ashman   Senior Vice President, European Managing Director
David Burke   Vice President
Mark J. Brooks   Independent Director
Brian K. Halak Ph.D.   Independent Director
James R. Largent   Independent Director
Peter J. Pizzo III   Independent Director

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE via CMTX - Wed Apr 27, 8:02AM CDT


Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results
Mar 2, 2016

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ALIM News: Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland 12/11/2017 07:30:00 AM
ALIM News: Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology 11/08/2017 07:30:00 AM
ALIM News: Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017 11/07/2017 07:30:00 AM
ALIM News: Notice of Effectiveness (effect) 11/06/2017 06:02:09 AM
ALIM News: Quarterly Report (10-q) 11/03/2017 04:57:10 PM
#853  Sticky Note Alimera Sciences and Knight Therapeutics Announce Filing of mick 02/22/17 08:47:22 AM
#899   Trying to get some @ 1.30, let's see Corpsman2012 12/14/17 01:23:44 PM
#898 mick 12/01/17 06:23:35 AM
#897   thank you/ Alimera Sciences, In (ALIM) mick 11/29/17 01:13:35 PM
#896   $$$$$ CarlCarlMcB 11/28/17 06:31:20 AM
#895 mick 10/08/17 02:13:00 PM
#894   Alimera Sciences, In (ALIM) mick 08/31/17 03:41:35 PM
#893   .0001 CarlCarlMcB 07/13/17 06:14:11 PM
#892   Alimera Sciences, In (ALIM) mick 07/09/17 11:45:15 AM
#891   ALIM News: Quarterly Report (10-q) 05/11/2017 09:13:51 AM mick 05/24/17 07:34:57 AM
#890   Alimera Sciences, In (ALIM) mick 05/24/17 07:34:50 AM
#889   $ALIM mick 05/13/17 12:12:07 PM
#888   I listened to the CC this morning.E Europe is bbhuey 05/09/17 07:02:04 PM
#887   The mouse ran up the clock. UserBob 05/02/17 08:38:32 AM
#886   Alimera Sciences, In (ALIM) mick 04/21/17 08:54:46 AM
#885   .12 CarlCarlMcB 04/21/17 05:06:42 AM
#884   interesting stuff/ $ALIM mick 04/19/17 04:42:17 PM
#883   Tick tock (.) CarlCarlMcB 04/19/17 03:09:01 PM
#882   Alimera Sciences, In (ALIM) mick 04/08/17 01:19:26 PM
#881   ALIM News: Statement of Changes in Beneficial Ownership mick 03/22/17 06:09:56 PM
#880   Alimera Sciences, In (ALIM) mick 03/22/17 06:09:46 PM
#879   .0001 CarlCarlMcB 03/22/17 04:47:22 PM
#878   Yep. Come on .50 CarlCarlMcB 03/21/17 07:14:26 PM
#877   If so, I'll be buying! UserBob 03/21/17 11:22:43 AM
#876   I might be right, .50 CarlCarlMcB 03/21/17 07:22:04 AM
#875   ALIM Long! UserBob 03/16/17 09:55:40 PM
#874   I was hoping for .50 CarlCarlMcB 03/16/17 06:44:49 PM
#873   Yep. $$$$$ Go Big !!! CarlCarlMcB 03/16/17 06:42:49 PM
#872   Carl, Hitting $2.00 tomorrow wine maker 03/16/17 06:19:04 PM
#871   Hehehehe rnoutlaw21 03/16/17 03:02:50 PM
#870   Haha keep raising your pt. Stock up 20% rnoutlaw21 03/14/17 12:18:56 PM
#869   .25 come on let's go ! Down ! CarlCarlMcB 03/14/17 12:17:22 PM
#868   Yes it is, for longs rnoutlaw21 03/13/17 10:18:29 AM
#867   Looking good Lol CarlCarlMcB 03/13/17 09:50:22 AM
#866   Raised from .00001? Haha how's that short rnoutlaw21 03/10/17 05:02:46 PM
#865   .25 CarlCarlMcB 03/04/17 05:37:37 AM
#864   .0001 CarlCarlMcB 03/01/17 07:46:52 AM
#863   Alimera long. UserBob 02/28/17 08:02:32 AM
#862   Lol mikekrane 02/27/17 08:08:49 AM
#861   You know the zero's Lol. CarlCarlMcB 02/27/17 08:07:55 AM
#860   your here? i guess i dont need to mikekrane 02/23/17 08:16:54 AM
#859   Downward trend .0001 CarlCarlMcB 02/23/17 05:50:16 AM
#858   Hey guys havent folowed this one in a Zack2000 02/22/17 09:00:28 PM
#857   Timber CarlCarlMcB 02/22/17 02:02:19 PM
#856   Hey why so quiet today? rnoutlaw21 02/22/17 01:50:50 PM
#855   ALIM News: Alimera Sciences and Knight Therapeutics Announce mick 02/22/17 12:08:43 PM
#854   Alimera Sciences, In (ALIM) mick 02/22/17 12:08:34 PM
#853   Alimera Sciences and Knight Therapeutics Announce Filing of mick 02/22/17 08:47:22 AM
#852   Payday is coming. UserBob 02/22/17 12:43:48 AM
#851   Oh, I know I'm just messing around too, rnoutlaw21 02/21/17 08:58:58 PM
#850   I'd recommend you stop wasting energy on this salgovernale69 02/21/17 08:30:43 PM